Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Probuphine buprenorphine hydrochloride Opioid drug dependence, treatment Reimburse with clinical criteria and/or conditions Complete
Procysbi cysteamine bitartrate Nephropathic cystinosis Reimburse with clinical criteria and/or conditions Complete
Proleukin Aldesleukin (IL-2) In-transit Melanoma Reimburse Complete
Prolia Denosumab (Drug Plan Submission) Osteoporosis, men List with clinical criteria and/or conditions Complete
Prolia Denosumab Osteoporosis, postmenopausal women List with clinical criteria and/or conditions Complete
Prolia Denosumab Osteoporosis Reimburse with clinical criteria and/or conditions Complete
Qinlock ripretinib Gastrointestinal stromal tumours Reimburse with clinical criteria and/or conditions Complete
Quinsair Levofloxacin Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections Reimburse with clinical criteria and/or conditions Complete
Qulipta atogepant Migraine, prevention Reimburse with clinical criteria and/or conditions Complete
Qulipta atogepant Migraine, prevention Reimburse with clinical criteria and/or conditions Active